1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Page is an informational hub; links to separate funding opportunities page for active FOAs.
Special Statutory Funding Program for Type 1 Diabetes Research is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) / NIH. This federal program supports research on the prevention and cure of type 1 diabetes and its complications. The NIDDK oversees this program in collaboration with multiple NIH Institutes and Centers and CDC.
Get alerted about grants like this
Get emailed when new opportunities from “National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) / NIH” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Type 1 Diabetes Special Statutory Funding Program - NIDDK Type 1 Diabetes Special Statutory Funding Program Type 1 Diabetes Special Statutory Funding Program The Special Statutory Funding Program for Type 1 Diabetes Research, or Special Diabetes Program, is a special appropriation that supports research on the prevention and cure of type 1 diabetes and its complications.
Since 1998, the Special Diabetes Program has enabled the creation of unique, innovative, and collaborative research consortia and clinical trials networks . These have made significant research progress as noted in program reports and also generated numerous research resources for use by the broad scientific community.
The NIDDK administers the Special Diabetes Program on behalf of the Secretary of the Department of Health and Human Services, in collaboration with multiple NIH Institutes and Centers and the CDC, and with input from the Diabetes Mellitus Interagency Coordinating Committee . Learn more about the Program’s background .
The Special Diabetes Program supplements type 1 diabetes research supported by the NIDDK and NIH’s regular appropriation. Therefore, the links on this site do not represent the entirety of type 1 diabetes research supported by the NIDDK and the NIH, but rather focus only on research supported by the Special Diabetes Program. Learn more about NIDDK diabetes research .
Clinical Trials Recruiting Patients and Families Opportunities for participation in human research studies on type 1 diabetes View Clinical Trials Recruiting Patients & Families Announcements of solicitations to conduct type 1 diabetes research Programs for Small Businesses Materials and tools to enable type 1 diabetes research by the broad scientific community Ancillary Studies to major Ongoing Clinical Trials Consortia, Networks, and Centers Programs funded to create communities of researchers focused on answering complicated scientific questions together Basic and Pre-Clinical Research Consortia Clinical Research Consortia and Networks Standardization of Laboratory Measurements View Consortia, Networks and Centers Information on research activities and advances, goals, and coordination in type 1 diabetes research Federal Diabetes Research Coordination View Reports and Planning
According to the current listing, eligibility includes: Research institutions and organizations, administered by NIDDK in collaboration with multiple NIH Institutes and Centers and CDC. Confirm the full requirements in the official notice before applying.
The current listing shows $150 million annually (total program funding). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Special Statutory Funding Program for Type 1 Diabetes Research is funded by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) / NIH. Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) & National Institutes of Health (NIH). This interagency program supports high-risk, high-reward advances in AI and data science for biomedical and public health research. Projects must cross disciplinary boundaries.
As of October 1, 2025, NIH no longer posts Notices of Funding Opportunity in the NIH Guide — Grants.gov is now the single official source (NOT-OD-25-143). The weekly Guide table-of-contents email that thousands of investigators relied on to discover funding no longer lists opportunities. Combined with the January 25, 2026 SciENcv certified-PDF requirement, the mechanics of finding and applying for NIH money have changed underneath everyone. Here is how to rebuild your discovery workflow so nothing slips through.
Read articleThe HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleThe NIH Director's New Innovator Award (DP2, RFA-RM-27-002) closes August 17, 2026, offering roughly 30 Early Stage Investigators up to $475,000 in direct costs a year for five years — $2.375 million total — to pursue bold ideas without the preliminary data a standard R01 demands. Here is how the High-Risk, High-Reward program actually evaluates applications, who qualifies, and why the usual R01 instincts will sink you.
Read article